StockTake: LTR’s new appointment rises to the occasion

LTR Pharma appoints Associate Professor Darren Katz to its scientific advisory board to consult for Spontan.

LTR Pharma (ASX:LTP) appoints Associate Professor Darren Katz to its scientific advisory board to spearhead consultancy for Spontan, LTR's innovative nasal spray treatment for erectile dysfunction.

Katz is a prominent urologist and medical director of Men’s Health Melbourne, and will advise on R&D along with clinical development activities for Spontan and Roxus, whilst engaging with key international opinion leaders to expanding LTR's prescriber networks. 

Watch the video to hear more.

This video was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial.